Cargando…
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
Therapeutic options for the treatment of colorectal cancer (CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hyper-mutated tumors suggests a permanent role of immune therapy in the clinical mana...
Autores principales: | Wagner, Sandra, Mullins, Christina S, Linnebacher, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319136/ https://www.ncbi.nlm.nih.gov/pubmed/30622371 http://dx.doi.org/10.3748/wjg.v24.i48.5418 |
Ejemplares similares
-
Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma
por: Mullins, Christina S, et al.
Publicado: (2011) -
T cells of colorectal cancer patients’ stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells
por: Schwarz, Sandra, et al.
Publicado: (2022) -
Mouse models of colorectal cancer: Past, present and future perspectives
por: Bürtin, Florian, et al.
Publicado: (2020) -
Neoantigen vaccine: an emerging tumor immunotherapy
por: Peng, Miao, et al.
Publicado: (2019) -
Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development
por: Kdimati, Said, et al.
Publicado: (2021)